This study describes a widespread variation in medication adherence, pharmacy cost sharing, and medical spending. Increased cost sharing may decrease adherence and increase total diabetes spending.
Iftekhar Kalsekar, PhD
Advertisement
Articles by Iftekhar Kalsekar, PhD
Given the growing prevalence of type 2 diabetes (T2D) and its contribution to cardiovascular disease, cardiovascular outcomes trials should aim to be more representative of the average patient with T2D.
Retrospective analysis of medical and pharmacy claims for patients diagnosed with schizophrenia or bipolar disorder in 24 state Medicaid programs.
Advertisement
Latest Updated Articles
- Representativeness of Dipeptidyl-Peptidase-4 Inhibitor Cardiovascular Outcomes Trials
Published: September 20th 2016 | Updated:
- The Relationship Between Adherence and Total Spending Among Medicare Beneficiaries With Type 2 Diabetes
Published: April 19th 2017 | Updated:
- Formulary Restrictions on Atypical Antipsychotics: Impact on Costs for Patients With Schizophrenia and Bipolar Disorder in Medicaid
Published: February 24th 2014 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
In Its 50th Year, ESMO Comes to Berlin, a City Transformed
2
Medicare State Rankings Reveal Stark Differences in Access, Quality, and Affordability
3
Physical Activity, Vaccination May Protect Against Long COVID
4
AI Tools Reduce Burnout in Health Care Workers
5
